Polaryx Therapeutics

Historical price data

Polaryx Therapeutics is a clinical-stage biotech company focused on developing disease-modifying treatments for rare pediatric lysosomal storage disorders (LSDs). Its core achievement is advancing PLX-200, an autophagy-inducing small molecule, into a Phase 2 basket trial (SOTERIA) for multiple LSDs, supported by multiple FDA designations including Orphan Drug, Fast Track, and Rare Pediatric Disease. The company's strategy is to build a diversified, multi-modal pipeline—encompassing small molecules and gene therapy—to target both the genetic and downstream pathological features of these diseases, aiming to establish a new standard of care.

Small molecule modulators of the autophagy-lysosome system, focusing on TFEB activation to enhance cellular clearance of toxic substrates, applicable across multiple lysosomal storage disorders.

Competition is fragmented; for CLN2, BioMarin's invasive infusion therapy Brineura sets a low bar for patient-friendliness. For other target LSDs (Krabbe, Sandhoff), there are no approved disease-modifying therapies, placing PLX-200 in a potential first-to-market position. Emerging gene therapies represent future competition but are single-indication and invasive.